Orion Pharma (DHA:ORIONPHARM) Other Financing: BDT-136 Mil (TTM As of Mar. 2026)


DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
69 GF Score
Price BDT28.60
GF Value BDT20.30
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma Other Financing?

Orion Pharma DHA:ORIONPHARM +0.35% 69 Other Financing is BDT-136 Mil as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 69/100 and a GF Value™ of BDT20.30 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Orion Pharma's Other Financing for the three months ended in Mar. 2026 was BDT-4 Mil.

Orion Pharma's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-136 Mil.

Orion Pharma Other Financing Historical Data

* Premium members only.

The historical data trend for Orion Pharma's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma Other Financing Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -488.68 -249.56 -401.76 -890.42 -155.04

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59.87 80.47 -83.26 -129.58 -3.52
DHA:ORIONPHARM
69GF Score
Orion Pharma Ltd DHA:ORIONPHARM
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Pharma Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-136 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of BDT-136 Mil mean?
Orion Pharma (DHA:ORIONPHARM) has a Other Financing of BDT-136 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Orion Pharma and its competitors.
Is Orion Pharma's Other Financing too high?
Orion Pharma's current Other Financing is BDT-136 Mil. Overall, Orion Pharma has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Other Financing compare to CEG and VST?
Orion Pharma's Other Financing of BDT-136 Mil can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for an Utilities - Independent Power Producers company?
A good Other Financing depends on the Utilities - Independent Power Producers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Orion Pharma and its competitors. Orion Pharma's current Other Financing is BDT-136 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.30, compared to a current price of BDT28.60 — trading 40.9% above its estimated fair value. The current Other Financing is BDT-136 Mil. Orion Pharma's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Other Financing is BDT-136 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT28.60 is trading 40.9% above its estimated GF Value™ of BDT20.30. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • Other Financing: BDT-136 Mil
  • GF Value™: BDT20.30 vs. price of BDT28.60 (40.9% above fair value)
  • GF Score™: 69/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
69GF Score

Get the complete analysis for DHA:ORIONPHARM

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT28.60
Price
BDT20.30
GF Value